Dual PPARα/γ agonist saroglitazar improves liver histopathology and biochemistry in experimental NASH models.
Jain, Mukul R
Dual PPARα/γ agonist saroglitazar improves liver histopathology and biochemistry in experimental NASH models. [electronic resource] - Liver international : official journal of the International Association for the Study of the Liver 06 2018 - 1084-1094 p. digital
Publication Type: Journal Article; Research Support, Non-U.S. Gov't
1478-3231
10.1111/liv.13634 doi
Alanine Transaminase--blood
Animals
Aspartate Aminotransferases--blood
Biomarkers--blood
Diet, High-Fat
Fenofibrate--pharmacokinetics
Hep G2 Cells
Humans
Kupffer Cells--drug effects
Liver--pathology
Male
Mice
Mice, Inbred C57BL
Non-alcoholic Fatty Liver Disease--drug therapy
PPAR alpha--agonists
Phenylpropionates--pharmacology
Pioglitazone--pharmacology
Pyrroles--pharmacology
Tumor Necrosis Factor-alpha--blood
Dual PPARα/γ agonist saroglitazar improves liver histopathology and biochemistry in experimental NASH models. [electronic resource] - Liver international : official journal of the International Association for the Study of the Liver 06 2018 - 1084-1094 p. digital
Publication Type: Journal Article; Research Support, Non-U.S. Gov't
1478-3231
10.1111/liv.13634 doi
Alanine Transaminase--blood
Animals
Aspartate Aminotransferases--blood
Biomarkers--blood
Diet, High-Fat
Fenofibrate--pharmacokinetics
Hep G2 Cells
Humans
Kupffer Cells--drug effects
Liver--pathology
Male
Mice
Mice, Inbred C57BL
Non-alcoholic Fatty Liver Disease--drug therapy
PPAR alpha--agonists
Phenylpropionates--pharmacology
Pioglitazone--pharmacology
Pyrroles--pharmacology
Tumor Necrosis Factor-alpha--blood